Novo Nordisk Launches Wegovy as First Oral Weight-Loss Pill in the U.S.

Novo Nordisk has launched an oral version of its weight-loss drug Wegovy in the U.S., offering a convenient alternative to injections. The pill, containing semaglutide, was approved by the FDA in December and is available for $149 per month for initial doses, with prices increasing later in April. Clinical trials show significant weight loss benefits, making it a notable innovation in obesity treatment.